Ebola vaccines

Thursday 1 July 2021 - Updated on Wednesday 18 August 2021
Learn about Epicentre's ongoing Ebola vaccines studies.

Zebovac

The study, "An open-label, single arm study to provide additional information on immunogenicity and safety of Ad26.ZEBOV/MVA-BN®-Filo" is an interventional, single arm, open-label, non-randomized, phase II study to accumulate additional data on immunogenicity and safety of the two vaccines Ad26.ZEBOV/MVA-BN®-Filo against Ebola virus disease. The primary objective is to to assess the humoral immune responses as measured by enzyme-linked immunosorbent assay (ELISA) to the Ebola glycoprotein after intramuscular administration of the vaccine in all participants. Safety, serious adverse event reporting and follow-up on outcomes of pregnancy, is the second primary objectives of this study.

 

Country

Uganda

Tentative End date

December 2021

Our Role

Scientific Oversight, Study Site

 

For more information contact: Rebecca Grais


 

TUJIOKOWE

The purpose of this study, "evaluation of the field efficacy and safety of a two-dose heterologous Ebola prophylaxis vaccine in the Democratic Republic of Congo", is to vaccinate with one of the candidate vaccines, VAC52150 (Ad26. ZEBOV, MVA-BN®-Filo), in order to determine the field efficacy of the vaccine regimen to prevent EVD through a case-control (test-negative) study and to document the activities related to the implementation of a two-dose regimen in this setting. This study is an open, nonrandomized study of the Ad26.ZEBOV/MVA-BN-Filo vaccine regimen in a population of eligible adults and children. The objective is to estimate the field efficacy of vaccination of the population with the Ad26.ZEBOV / MVA-BN-Filo vaccination regimen for the prevention of EVD in adults and children at least 1 year of age.

 

Country

Democratic Republic of Congo

Tentative End date

February 2022

Our Role

Scientific Oversight, Data, Management, Monitoring and PV, Capacity Building

 

For more information contact: Rebecca Grais